Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | IR plus R-HCVAD/R-MTX efficacious for young MCL in the first-line

Preetesh Jain • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Rituximab

A study of ibrutinib-rituximab plus short course R-HCVAD/R-MTX for previously untreated, young mantle cell lymphoma (MCL) patients was presented by M. Wang at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, his colleague Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the findings.

More from Preetesh Jain

5:06
Trials of interest in the mantle cell lymphoma space at ASH 2023
Preetesh Jain • 8 Dec 2023
0:58
Future work in mantle cell lymphoma
Preetesh Jain • 15 Jun 2023
1:32
Selecting BTK inhibitors for patients with MCL
Preetesh Jain • 15 Jun 2023
1:18
The unmet needs of patients with MCL who relapse after CAR-T
Preetesh Jain • 15 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals